Bleomycin
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Bleomycin and local guidelines before prescribing.
Mechanism
Glycopeptide antibiotic causing DNA strand breaks.
Uses
Testicular cancer, Hodgkin lymphoma, squamous cancers, pleurodesis.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Pulmonary fibrosis, skin pigmentation, fever, mucositis.
Interactions
Oxygen at high concentration worsens lung toxicity; cisplatin increases toxicity.
Contraindications and cautions
Pulmonary fibrosis, severe lung disease
Monitoring
Lung function, CXR, renal function
Pregnancy and breastfeeding
Contraindicated
Renal and hepatic impairment
Reduce dose in renal impairment
Overdose and reversal
Supportive
Special advice
Record cumulative dose; lung function tests; avoid high FiO2 in anaesthesia.
More from the textbook: uses, cautions and other points
- Bleomycin | Pulmonary fibrosis (dose-related; avoid high oxygen concentrations later)
Respiratory: Anatomy, Physiology and Pharmacology - Bleomycin - lung fibrosis; cisplatin - kidney toxicity, hearing loss, neuropathy, low magnesium.
Haematology: Anatomy Physiology and Pharmacology - Advanced stage: ABVD with an interim PET-CT after 2 cycles . If PET-negative (Deauville 1–3) bleomycin is dropped (AVD) to reduce lung toxicity (RATHL trial); if PET-positive, treatment is escalated. Brentuximab vedotin-based regimens and BrECADD are used in some patients.
Haematology: Myeloma and Lymphoma - Heart disease and cardiomyopathy (mediastinal radiotherapy plus anthracycline); bleomycin lung toxicity - tell anaesthetists and avoid unnecessarily high oxygen concentrations.
Haematology: Myeloma and Lymphoma - ABVD | Hodgkin lymphoma: doxorubicin (cardiotoxic), bleomycin (pulmonary fibrosis) , vinblastine, dacarbazine (nausea); omit bleomycin if interim PET-negative.
Haematology: Myeloma and Lymphoma - Drugs damaging lungs: amiodarone, methotrexate, nitrofurantoin, bleomycin, checkpoint inhibitors.
Respiratory: Anatomy, Physiology and Pharmacology - Chemotherapy - bleomycin (made worse by high oxygen), busulfan, cyclophosphamide.
Respiratory: Interstitial Lung Disease - Drug-induced ILD: methotrexate, amiodarone, nitrofurantoin, bleomycin, checkpoint inhibitors - stop the drug.
Respiratory: Interstitial Lung Disease
Where it is discussed in the book
- Respiratory: Anatomy, Physiology and Pharmacology (2 mentions)
- Respiratory: Interstitial Lung Disease (2 mentions)
- Haematology: Anatomy Physiology and Pharmacology (1 mention)
- Haematology: Myeloma and Lymphoma (8 mentions)
- Oncology: Principles (3 mentions)
- Oncology: Urology and Genital cancers (2 mentions)
- Rheumatology: Connective tissue diseases (1 mention)
- Surgey: Urology (1 mention)
- Clinical pharmacology and prescribing: Adverse drug reactions, interactions and drug allergy (1 mention)
- Clinical imaging: Chest X-ray and cardiothoracic imaging (1 mention)
- Integrated respiratory chapter (2 mentions)
- Cell Biology: Cell cycle, signalling, cell death and stem cells (1 mention)